Table 1.

Death and neurological disability after transient fMCAO in S218L mutant mice.

Experiment	60 min fMCAO*			60 min fMCAO + MK-801†#		30 min fMCAO‡
Gender, Genotype	Male WT	Male HET	Male HOM	Male WT	Male HET	Male WT	Male HET	Male HOM	Female WT	Female HET
N	9	23	8	9	10	9	5	4	6	8
Mortality	11%	35%	100%	0%	10%	0%	0%	75%	0%	0%
Functional outcome score	2 [2–3]	3 [2–5]	5 [5–5]	2 [1–2]	2 [1–2]	1 [1–2]	2 [1–2]	5 [4–5]	1 [0.3–1]	2 [1–2]

Functional outcome scores are shown as median [interquartile range]. 0 = best, 5 = worst, see Methods for the scoring system.

^*p<0.001 and p=0.008 for the effect of genotype on mortality and functional outcome score, respectively.

^†p=0.353 and p=0.757 for the effect of genotype on mortality and functional outcome score, respectively.

^#p=0.303 and p=0.315 for the effect of MK-801 on mortality and functional outcome score, respectively, in WT, and p=0.022 and p=0.009 for the effect of MK-801 on mortality and functional outcome score, respectively, in the S218L HET, compared to the untreated group.

^‡p<0.001 and p=0.086 for the effect of genotype on mortality and functional outcome score in males, respectively, and p=0.02 for the effect of genotype on functional outcome score in females, after 30 min fMCAO. In the R192Q mutant strain, the mortality rate was 17%, 0% and 14% in WT, HET and HOM, respectively; neurological disability was not studied in this mutant strain.